Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Bayer Head of Discovery Exits as Drugmaker Combines Pharma R&D Unit November 29, 2017 University Enterprise Laboratories Announces Partnership With (UMGC) July 13, 2017 Viking Therapeutics Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update March 21, 2017
Viking Therapeutics Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update March 21, 2017